Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

RR001, a cell-based gene therapy administered following chemotherapy cycles for the treatment of patients with locally advanced pancreatic cancer. Phase I /IIa clinical trial (open label and non-randomized) to test the effects (safety \& efficacy) of increasing doses of RR001

Trial Details

NCT ID
NCT06861452
Phase
PHASE1 / PHASE2
Sponsor
EIR Biotherapies s.r.l.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • RR001
Locations (sample)
  • Modena, Italy, Italy|44.64783,10.92539

Key Eligibility Criteria

  • Patients with confirmed pancreatic ductal adenocarcinoma classified as locally advanced pancreatic adenocarcinoma (LPAC)
  • Patients with no evidence of peritoneal or hematogenous metastasis
  • Patients classified as non-resectable locally advanced pancreatic carcinoma (LAPC) based on imaging (TC and NMR), on multidisciplinary staff evalua…
  • Measurable tumor according RECIST criteria v 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →